Table 4.
IPA analysis of exosome proteins present in African American men with PCa
| P‐value | |
|---|---|
| Top canonical pathways | |
| Acute‐phase response signaling | 4.68E−24 |
| Complement System | 6.55E−14 |
| LXR/RXR Activation | 5.94E−12 |
| FXR/RXR Activation | 4.92E−10 |
| Hematopoiesis from Pluripotent Stem Cells | 6.20E−07 |
| Top upstream regulators | |
| HNF1A | 3.86E−10 |
| IL6 | 2.82E−09 |
| CEBPB | 8.50E−08 |
| Nitrofurantoin | 1.22E−07 |
| Lipopolysaccharide | 2.75E−07 |
| Top diseases and biofunctions | |
| Diseases and disorders | |
| Developmental disorder | 1.46E−03‐6.84E−14 |
| Hereditary disorder | 1.46E−03‐6.84E−14 |
| Immunological disease | 1.45E−03‐6.84E−14 |
| Organismal injury and abnormalities | 1.46E−03‐6.84E−14 |
| Neurological disease | 1.45E−03‐6.36E−12 |
| Molecular and cellular functions | |
| Cell‐to‐cell signaling and interaction | 1.46E−03‐1.68E−09 |
| Molecular transport | 1.46E−03‐1.97E−08 |
| Cellular assembly and organization | 1.45E−03‐9.65E−08 |
| Cell death and survival | 1.45E−03‐1.54E−07 |
| Cellular compromise | 1.45E−03‐2.88E−07 |
| Physiological system development and function | |
| Humoral immune response | 1.45E−03‐7.49E−11 |
| Hematological system development and function | 1.45E−03‐1.68E−09 |
| Immune cell trafficking | 1.45E−03‐2.01E−08 |
| Tissue morphology | 1.45E−03‐1.41E−07 |
| Tissue development | 1.46E−03‐1.67E−07 |